{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:09:03Z","timestamp":1791918543928,"version":"4.3.4"},"reference-count":39,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T00:00:00Z","timestamp":1703116800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"\u201c345 Talent Project\u201d of Shengjing Hospital of China Medical University"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Introduction: Trifluridine\/tipiracil (TAS-102) and fruquintinib are novel antitumor agents for patients with refractory metastatic colorectal cancer (mCRC). We conducted a retrospective study to explore the clinical efficacy and drug toxicities of combination therapy with TAS-102 and fruquintinib in real-life clinical practice. Methods: Between March 2021 and February 2023, patients at two different centers with mCRC who failed two or more lines of prior therapy and received TAS-102 in combination with fruquintinib were recruited. Results: In total, 32 mCRC patients were included in the analysis. The objective response rate (ORR) and the disease control rate (DCR) were 9.4% and 75%. The median progression-free survival (PFS) and overall survival (OS) were 6.3 (95% CI: 5.3\u20137.3) and 13.5 (95% CI: 9.5\u201317.5) months, respectively. Patients without liver metastasis or peritoneal metastasis obtained better median PFS (7.1 m vs. 5.6 m, p = 0.03 and 6.3 m vs. 3.4 m, p = 0.04), and OS (15.2 m vs. 10.4 m, p = 0.01 and 13.6 m vs. 7.1 m, p = 0.03), respectively. Other clinicopathological features, including age, tumor site, KRAS status, dosage of fruquintinib, and treatment line, did not affect the clinical efficacy of TAS-102 combined with fruquintinib. The most common grade three\u2013four toxicities were neutropenia (46.9%), anemia (21.9%), diarrhea (15.6%), nausea (12.5%), and hand\u2013foot syndrome rash (12.5%). Conclusions: Our results suggest that TAS-102 combined with fruquintinib has promising clinical efficacy and manageable safety for refractory mCRC patients in a real-world clinical setting. Further prospective trials are warranted to confirm our results.<\/jats:p>","DOI":"10.3390\/jcm13010057","type":"journal-article","created":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T10:53:52Z","timestamp":1703156032000},"page":"57","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["A Retrospective Study of Trifluridine\/Tipiracil with Fruquintinib in Patients with Chemorefractory Metastatic Colorectal Cancer"],"prefix":"10.3390","volume":"13","author":[{"given":"Jiayun","family":"Zou","sequence":"first","affiliation":[{"name":"Department of Oncology, Shengjing Hospital of China Medical University, Shenyang 110004, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Shengjing Hospital of China Medical University, Shenyang 110004, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayu","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of VIP In-Patient Ward, the First Hospital of China Medical University, Shenyang 110001, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinna","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Oncology, Shengjing Hospital of China Medical University, Shenyang 110004, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianzhuo","family":"Wang","sequence":"additional","affiliation":[{"name":"The First Clinical College, China Medical University, Shenyang 110122, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Shengjing Hospital of China Medical University, Shenyang 110004, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yibo","family":"Bai","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Shengjing Hospital, China Medical University, Shenyang 110004, China"},{"name":"Liaoning Clinical Research Center for Laboratory Medicine, Shenyang 110004, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,12,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer. J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","article-title":"Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Cervantes","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1200\/JCO.2008.19.9273","article-title":"Patients with initially unresectable colorectal liver metastases: Is there a possibility of cure?","volume":"7","author":"Adam","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1165666","DOI":"10.3389\/fphar.2023.1165666","article-title":"Molecular targeted therapy for metastatic colorectal cancer: Current and evolving approaches","volume":"14","author":"Li","year":"2023","journal-title":"Front. Pharmacol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"17588359211072703","DOI":"10.1177\/17588359211072703","article-title":"Precision medicine for metastatic colorectal cancer in clinical practice","volume":"14","author":"Riedesser","year":"2022","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"403","DOI":"10.21147\/j.issn.1000-9604.2020.03.11","article-title":"Updates in version 2020 of CSCO guidelines for colorectal cancer from version 2019","volume":"32","author":"Weng","year":"2020","journal-title":"Chin. J. Cancer. Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1586\/14737140.2015.1105746","article-title":"TAS-102 for the treatment of metastatic colorectal cancer","volume":"15","author":"Salvatore","year":"2015","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","article-title":"Randomized trial of TAS-102 for refractory metastatic colorectal cancer","volume":"372","author":"Mayer","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1200\/JCO.2017.74.3245","article-title":"Results of a randomized, double-blind, placebo\u2013 controlled, phase III trial of trifluridine\/tipiracil (TAS-102) monotherapy in Asian patients with previously treated metastatic colorectal cancer: The TERRA study","volume":"36","author":"Xu","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/S1470-2045(17)30425-4","article-title":"TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): An investigator-initiated, open-label, single-arm, multicentre, phase 1\/2 study","volume":"18","author":"Kuboki","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/S1470-2045(19)30827-7","article-title":"TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: An investigator-initiated, open-label, randomised, phase 2 trial","volume":"21","author":"Pfeiffer","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1200\/JCO.2023.41.4_suppl.4","article-title":"Triuridine\/tipiracil plus bevacizumab for third-line treatment of refractory metastatic colorectal cancer: The phase 3 randomized SUNLIGHT study","volume":"41","author":"Tabernero","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1038\/bjc.2011.81","article-title":"Chronic exposure of colorectal cancer cells to bevacizumab promotes compensatory pathways that mediate tumor cell migration","volume":"104","author":"Fan","year":"2011","journal-title":"Br. J. Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Itatani, Y., Kawada, K., Yamamoto, T., and Sakai, Y. (2018). Resistance to Anti-Angiogenic Therapy in Cancer\u2014Alterations to Anti-VEGF Pathway. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19041232"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.2018.7855","article-title":"Effect of Fruquintinib vs. Placebo on Overall Survival in Patients with Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial","volume":"319","author":"Li","year":"2018","journal-title":"JAMA"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Dasari1, N.A., Lonardi, S., Garcia-Carbonero, R., Elez Fernandez, M.E., Yoshino, T., Sobrero, A.F., Yao, J.C., Garc\u00eda-Alfonso, P., Kocsis, J., and Cubillo Gracian, A. (2022). FRESCO-2: A global phase III multiregional clinical trial (MRCT) evaluating the efficacy and safety of fruquintinib in patients with refractory metastatic colorectal cancer. Ann. Oncol., 33, S1392.","DOI":"10.1016\/j.annonc.2022.08.021"},{"key":"ref_17","first-page":"2135","article-title":"Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, together with bevacizumab, cetuximab, or panitumumab on human colorectal cancer xenografts","volume":"33","author":"Tsukihara","year":"2015","journal-title":"Oncol. Rep."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1159\/000528867","article-title":"Evaluation of a Novel Combination Therapy, based on Trifluridine\/Tipiracil and Fruquintinib against Colorectal Cancer","volume":"68","author":"Nukatsuka","year":"2023","journal-title":"Chemotherapy"},{"key":"ref_19","unstructured":"National Cancer Institute Division of Cancer Treatment and Diagnosis (2022, April 28). Common Terminology Criteria for Adverse Events (CTCAE), Available online: https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm#ctc_40."},{"key":"ref_20","first-page":"277","article-title":"Different mechanisms of acquired resistance to fluorinated pyrimidines in human colorectal cancer cells","volume":"17","author":"Murakami","year":"2000","journal-title":"Int. J. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"13438","DOI":"10.18632\/oncotarget.24412","article-title":"Trifluridine\/tipiracil overcomes the resistance of human gastric 5-fluorouracil-refractory cells with high thymidylate synthase expression","volume":"9","author":"Matsuoka","year":"2018","journal-title":"Oncotarget"},{"key":"ref_22","first-page":"4605","article-title":"Efficacy of combination chemotherapy using a novel Oral chemotherapeutic agent, TAS-102, with Oxaliplatin on human colorectal and gastric Cancer Xenografts","volume":"35","author":"Nukatsuka","year":"2015","journal-title":"Anticancer Res."},{"key":"ref_23","first-page":"1437","article-title":"Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, with irinotecan hydrochloride on human colorectal and gastric cancer xenografts","volume":"35","author":"Nukatsuka","year":"2015","journal-title":"Anticancer Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s12307-015-0173-y","article-title":"Thymidine Phosphorylase in Cancer; Enemy or Friend?","volume":"9","author":"Elamin","year":"2016","journal-title":"Cancer Microenviron."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.18632\/oncotarget.1811","article-title":"Biomarkers of reactive resistance and early disease progression during chemotherapy plus bevacizumab treatment for colorectal carcinoma","volume":"5","author":"Hayashi","year":"2014","journal-title":"Oncotarget"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1758835920956862","DOI":"10.1177\/1758835920956862","article-title":"Practical considerations in the use of regorafenib in metastatic colorectal cancer","volume":"12","author":"Loupakis","year":"2020","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s00280-014-2471-3","article-title":"Preclinical pharmacokinetics and disposition of a novel selective VEGFR inhibitor fruquintinib (HMPL-013) and the prediction of its human pharmacokinetics","volume":"74","author":"Gu","year":"2014","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1080\/13696998.2021.1888743","article-title":"Cost-effectiveness analysis of fruquintinib versus regorafenib as the third-line therapy for metastatic colorectal cancer in China","volume":"24","author":"Guan","year":"2021","journal-title":"J. Med. Econ."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1067\/j.cpsurg.2018.08.004","article-title":"Cytoreduction for Colorectal Metastases: Liver, Lung, Peritoneum, Lymph Nodes, Bone, Brain. When Does it Palliate, Prolong Survival, and Potentially Cure?","volume":"55","author":"Stewart","year":"2018","journal-title":"Curr. Probl. Surg."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1200\/JCO.2011.37.1039","article-title":"Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: A pooled analysis of north central cancer treatment group phase III trials N9741 and N9841","volume":"30","author":"Franko","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.2217\/fon-2020-1215","article-title":"Quality-adjusted survival in patients with metastatic colorectal cancer treated with fruquintinib in the FRESCO trial","volume":"17","author":"Qin","year":"2021","journal-title":"Future Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1200\/JCO.1997.15.1.110","article-title":"Patient preferences for oral versus intravenous palliative chemotherapy","volume":"15","author":"Liu","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Matsuoka, K., Nakagawa, F., Tanaka, N., Okabe, H., Matsuo, K., and Takechi, T. (2018). Effective Sequential Combined Chemotherapy with Trifluridine\/Tipiracil and Regorafenib in Human Colorectal Cancer Cells. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19102915"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.3892\/ijo.2015.2974","article-title":"Crucial roles of thymidine kinase 1 and deoxyUTPase in incorporating the antineoplastic nucleosides trifluridine and 2\u2019-deoxy-5-fluorouridine into DNA","volume":"46","author":"Sakamoto","year":"2015","journal-title":"Int. J. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/bjc.2016.413","article-title":"Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer","volume":"116","author":"Marmorino","year":"2017","journal-title":"Br. J. Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"100740","DOI":"10.1016\/j.tranon.2020.01.001","article-title":"hERG1 and HIF-2 Behave as Biomarkers of Positive Response to Bevacizumab in Metastatic Colorectal Cancer Patients","volume":"13","author":"Iorio","year":"2020","journal-title":"Transl. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ejca.2022.01.025","article-title":"Early modulation of Angiopoietin-2 plasma levels predicts benefit from regorafenib in patients with metastatic colorectal cancer","volume":"165","author":"Antoniotti","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e15012","DOI":"10.1200\/JCO.2019.37.15_suppl.e15012","article-title":"Association between hand-foot skin reaction (HFSR) and survival benefit of fruquintinib in FRESCO trial","volume":"37","author":"Li","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"372","DOI":"10.3322\/caac.21728","article-title":"Clinial management of metastatic colorectal cancer in the era of precision medicine","volume":"72","author":"Ciardiello","year":"2022","journal-title":"CA Cancer. J. Clin."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/1\/57\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:39:54Z","timestamp":1760132394000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/1\/57"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,21]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1]]}},"alternative-id":["jcm13010057"],"URL":"https:\/\/doi.org\/10.3390\/jcm13010057","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,21]]}}}